Roche stock could be interesting for patient investors. Learn more about its outlook, pipeline prospects, and upcoming ...

A campaign push by some Republicans to make contraceptive drugs available without a prescription has some support from medical groups despite objections from women's health advocates. New York City ...

Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.

EXCLUSIVE: Cancer patients, oncologists and advocates tell Rhian Lubin why the US health insurance system needs urgent reform, and is risking the lives of Americans fighting the disease ...

Detailed price information for Defence Therapeutics Inc (DTCFF) from The Globe and Mail including charting and trades.

In the comparative in vivo study, Accum®-Kadcyla demonstrated a ~20-fold higher anti-tumor efficacy than Kadcyla® alone when administered at the same dose (0.5 mg/kg). Tumor growth was significantly ...

Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate (ADC) bearing a deruxtecan (TOP1 inhibitor) warhead, was developed by Japanese pharmaceutical company Daichi Sankyo. A ...

Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugates (ADC): Market Overview" report has been added to ResearchAndMarkets.com's offering. The global ADC market grew from $50 million ...

– Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date – – Long-term data also showed continued benefit in invasive ...